Study on the Safety and Effectiveness of BGB-16673 Compared to Pirtobrutinib in Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Inclusion Criteria

• Have a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that requires treatment.
• Have previously been treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi) and have the disease return or not respond to at least one line of therapy, including a cBTKi.
• For those with SLL, have measurable disease on scans, with at least one lymph node larger than 1.5 cm in diameter.

Exclusion Criteria

• Have a known type of leukemia called prolymphocytic leukemia or a history of, or currently suspected, transformation to a more aggressive form known as Richter's transformation.
• Have a history of bleeding disorders like hemophilia or von Willebrand disease, or have experienced spontaneous bleeding that required medical treatment.
• Have had a stroke or bleeding in the brain within the last 6 months.
• Have previously been treated with any Bruton tyrosine kinase (BTK) protein degraders or noncovalent Bruton tyrosine kinase inhibitors (ncBTKi).
• Have current or past involvement of the central nervous system (brain, spinal cord, or surrounding areas) by CLL/SLL, as shown by imaging or tests.